Non-invasive in vivo imaging of acute thrombosis: development of a novel factor XIIIa radiotracer by Andrews, Jack et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-invasive in vivo imaging of acute thrombosis: development
of a novel factor XIIIa radiotracer
Citation for published version:
Andrews, J, Portal, C, Walton, T, Macaskill, M, Hadoke, P, Corral, CA, Lucatelli, C, Wilson, S, Macnaught,
G, Dweck, M, Newby, D & Tavares, A 2019, 'Non-invasive in vivo imaging of acute thrombosis:
development of a novel factor XIIIa radiotracer', European Heart Journal - Cardiovascular Imaging.
https://doi.org/10.1093/ehjci/jez207
Digital Object Identifier (DOI):
10.1093/ehjci/jez207
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
European Heart Journal - Cardiovascular Imaging
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. Nov. 2019
..
..
..
..
..
..
..
..
..
.
Non-invasive in vivo imaging of acute
thrombosis: development of a novel factor
XIIIa radiotracer
Jack P.M. Andrews 1*, Christophe Portal2, TashfeenWalton3, Mark G. Macaskill1,
PatrickW.F. Hadoke1, Carlos Alcaide Corral1, Christophe Lucatelli3, Simon
Wilson1, IanWilson4, Gillian MacNaught3, Marc R. Dweck1, David E. Newby1, and
Adriana A.S. Tavares1
1BHF Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh, UK; 2Edinburgh Molecular Imaging Ltd., 9 Little France Road, Edinburgh,
UK; 3Edinburgh Imaging facility QMRI, University of Edinburgh, 47 Little France Crescent, Edinburgh, UK; and 4ImaginAb, Inc. U.S. 43 Hindry Avenue, Suite D, Inglewood, California, USA
Received 8 May 2019; editorial decision 19 July 2019; accepted 7 August 2019
Aims Cardiovascular thrombosis is responsible a quarter of deaths annually worldwide. Current imaging methods for car-
diovascular thrombosis focus on anatomical identification of thrombus but cannot determine thrombus age or
activity. Molecular imaging techniques hold promise for identification and quantification of thrombosis in vivo. Our
objective was to assess a novel optical and positron-emitting probe targeting Factor XIIIa (ENC2015) as biomarker
of active thrombus formation.
...................................................................................................................................................................................................
Methods
and results
Optical and positron-emitting ENC2015 probes were assessed ex vivo using blood drawn from human volunteers and
passed through perfusion chambers containing denuded porcine aorta as a model of arterial injury. Specificity of
ENC2015 was established with co-infusion of a factor XIIIa inhibitor. In vivo 18F-ENC2015 biodistribution, kinetics,
radiometabolism, and thrombus binding were characterized in rats. Both Cy5 and fluorine-18 labelled ENC2015 rap-
idly and specifically bound to thrombi. Thrombus uptake was inhibited by a factor XIIIa inhibitor. 18F-ENC2015
remained unmetabolized over 8 h when incubated in ex vivo human blood. In vivo, 42% of parent radiotracer remained
in blood 60 min post-administration. Biodistribution studies demonstrated rapid clearance from tissues with elimin-
ation via the urinary system. In vivo, 18F-ENC2015 uptake was markedly increased in the thrombosed carotid artery
compared to the contralateral patent artery (mean standard uptake value ratio of 2.40 vs. 0.74, P< 0.0001).
...................................................................................................................................................................................................
Conclusion ENC2015 rapidly and selectively binds to acute thrombus in both an ex vivo human translational model and an
in vivo rodent model of arterial thrombosis. This probe holds promise for the non-invasive identification of throm-
bus formation in cardiovascular disease.
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Introduction
Acute vascular thrombosis is common to the pathogenesis of myo-
cardial infarction, stroke, and venous thromboembolism which col-
lectively are responsible for a quarter of all deaths annually
worldwide.1 At present, imaging approaches to the detection of
acute thrombosis consist mainly of thrombus visualization with
ultrasound, invasive catheterization, computerized tomography
(CT), and magnetic resonance angiography. Common to all of
these imaging modalities is a lack of sensitivity and specificity for
acute thrombus detection.2–4 None can accurately ascertain
whether a thrombus is physiologically active or dormant which can
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..make diagnostic and management decisions regarding anti-
thrombotic therapy difficult. These limitations support the devel-
opment of novel imaging techniques to detect acute vascular
thrombosis with greater precision.5
Molecular positron emission tomography (PET) imaging offers the
potential to address a number of these issues through visualization
and quantification of physiological thrombus activity.5 Thrombus
tracers have so far shown promise in monitoring thrombolysis effi-
cacy in rats6 and the detection of acute deep vein thrombosis and
pulmonary embolism in humans.7 However, none of these PET radio-
tracers targets the coagulation factor XIIIa (FXIIIa). In the present
study, we report on the development of a novel factor XIIIa-directed
optical and PET radiotracer, ENC2015 (Figure 1),8,9 for the non-
invasive imaging of thrombosis in vivo. ENC2015 is based on
99mTc-NC100668, a small single-photon emission computerized
tomography (SPECT) FXIIIa-targeted radiotracer. The coagulation
factor FXIIIa acts to strengthen fibrin crosslinking in newly formed
thrombus, thus serving as a valuable target to assess thrombus activ-
ity and age. Previously, binding of NC100668 to thrombus has been
demonstrated in in vitro plasma clot assays, a rat model of inferior
vena cava thrombosis, and human autopsy specimens of pulmonary
thromboemboli.10,11 In contrast to NC100668, ENC2015 is labelled
with the PET radioisotope fluorine-18 thus allowing for clinical imag-
ing datasets with higher resolution and improved quantification com-
pared with SPECT. Furthermore, ENC2015 was developed as both
an optical near-infrared fluorescent probe and an 18F positron-emit-
ting radiotracer to image thrombosis in vivo. A dual optical-PET
labelled probe would hold great promise for in vivo diagnosis and
histological tissue validation with a single chemical moiety. Moreover,
ENC2015 offers the potential to allow identification of disease before
clinical manifestation, track thrombus activity over time, and monitor
therapeutic efficacy. Here, we report our pre-clinical assessment of
ENC2015 in an ex vivo model of human thrombosis and an in vivo ro-
dent carotid thrombosis model.
Figure 1 Cy5 and fluorine-18 labelled chemical structure of ENC2015 compound. (A) The chemical structure of NC100668 upon which
ENC2015 is based.8,9 (B) The ENC2015 peptide with the optical Cy5 label. (C) The ENC2015 peptide after chelation with Al18F.
2 J.P.M. Andrews et al.
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Methods
Synthesis of ENC2015
The peptide scaffold of ENC2015 was prepared by Fmoc solid-phase
peptide synthesis using Rink amide Chemmatrix resin and HBTU/DIPEA
assisted couplings, monitored by Kaiser ninhydrin test and regular test
cleavages followed by HLPC and MALDI-TOF MS analyses. After the as-
sembly of the peptide and capping with Ac2O, the e-amine Mmt protect-
ing group on the Lysine residue at the C-terminus was deprotected on
resin and derivatised with sulfo Cy5 using PyBop as a coupling reagent.
Cy5-ENC2015 was obtained after cleaving off the peptide from the solid
support and semi-preparative HPLC purification in low yield (4% overall
yield) but excellent purity (>98% at 210 nm). The peptide precursor of
Al18F-ENC2015 [peptide with p-SCN-Bn-1,4,7-triazacyclononane-1,4,7-
triacetic acid (NOTA) chelator] was prepared by Fmoc solid-phase pep-
tide synthesis using Rink amide Chemmatrix resin and HBTU/DIPEA
assisted couplings, monitored by Kaiser ninhydrin test and regular test
cleavages followed by HLPC and MALDI-TOF MS analyses. After the as-
sembly of the peptide and capping with Ac2O, the e-amine Dde protect-
ing group on the Lysine residue at the C terminus was de-protected on
resin and derivatised with NOTA-NHS. The precursor was obtained
after cleavage from the solid support and purifying it by semi-preparative
HPLC purification in low yield (5% overall yield) but excellent purity
(>97% at 210 nm).
Radiolabelling of ENC2015
The radiosynthesis of 18F-ENC2015 was performed at Edinburgh Imaging
Facility on a commercial synthesizer, GE TRACERlabVR MX. A disposable
kit was assembled to allow the peptide conjugate to chelate with alumin-
ium fluoride and undergo purification using an automated method.
Purified Fluoride-18 (using SepPak QMA Light cartridge eluted with
300mL saline, ca. 10 GBq) was added to a mixture of NOTA-peptide
(12mL, 2 mM solution in NaOAc buffer pH 4) in the presence of AlCl3
(6mL, 2 mM in NaOAc buffer pH 4). Acetonitrile was used as an organic
co-solvent (aqueous solution to organic solvent ratio of 1:1.2 v/v) and the
mixture was heated to 100C for 10 min. The reaction mixture was
diluted with water (20 mL) and passed through a SepPak Light C18 cart-
ridge (pre-conditioned with ethanol and water). The C18 cartridge was
washed with water (2  20 mL) and product was eluted with ethanol
(1.5 mL). The final product was formulated in a physiological solution
containing 10% ethanol in normal saline. 18F-ENC2015 was obtained with
an average non-decay corrected yield of 27± 11% (starting from 10± 6
GBq of fluoride-18, n= 15) after a total synthesis time of 28 min. Identity
of 18F-ENC2015 and its radiochemical purity (>99%) were determined
by analytical HPLC (C18, 250  4.6 mm, 1 mL/min, UV absorbance at
k= 267 nm) at the end of the synthesis. 18F-ENC2015 specific activity
was >45 GBq/lmol.
Ex vivo translational model of human
thrombus formation
To confirm target engagement, we examined binding of ENC2015 to
newly formed thrombus using an ex vivo translational model of acute
thrombus formation (Supplementary data online, Figure S1) as described
previously.12–15 In brief, a pump (Masterflex model 7013, Cole-Palmer
Instruments, USA) was used to draw native (un-anticoagulated) blood
from the antecubital vein of healthy volunteers through a series of three
cylindrical perfusion chambers maintained at 37C in a water bath. Each
chamber contained a carefully prepared strip of porcine aorta (Pel-Freez
Biologicals, CA, USA) from which the intima and a thin layer of media had
been removed. Rheological conditions in the first chamber simulated
those of patent medium-sized coronary arteries (low-shear rate, 212 s-1),
whereas those in the second and third chambers simulated those of mild
to moderately stenosed coronary arteries (high shear rate, 1690 s-1).
Each study lasted for exactly 5 min during which flow was maintained at a
constant rate of 10 mL/min. Following perfusion of blood, the chambers
were perfused with 0.9% saline for one minute under the same rheologic-
al conditions. Thereafter, the porcine strips with thrombus attached
were removed and fixed in 4% paraformaldehyde for 24 h at 4C prior to
being prepared for histological analysis.
Sixteen healthy male volunteers (31 ± 1.26 years) were enrolled into
the study which was performed with the approval of the local research
ethics committee (AMREC; 17-HV-033), in accordance with the
Declaration of Helsinki, and the written informed consent of all the vol-
unteers. Exclusion criteria were history of bleeding diathesis, use of regu-
lar medication or any clinically significant illness. We conducted the study
in a series of sequences: (i) infusion of Cy5-ENC2015 (250 nM, n= 6) or
18F-ENC2015 (4.6± 0.5 MBq/mL, n= 10); (ii) infusion of Cy5-ENC2015
(250 nM, n= 6) or 18F-ENC2015 (5.5 ± 0.9 MBq/mL, n= 10) plus factor
XIIIa inhibitor (Iodoacetamide, Sigma-Aldrich, UK) at a concentration
10 mg/mL; and (iii) blood control without infusion of optical or radiola-
belled tracer (n= 6). For the optical probe, further control experimental
groups included: (iv) the administration of ENC2015 in the absence of
blood, (v) the infusion of free Cy5 fluorophore, and (vi) the infusion of a
scrambled peptide sequence (Supplementary data online, Figure S2B) in
the presence of thrombus. In one volunteer, we collected blood through
the chamber for HPLC radiometabolite analysis to assess tracer stability
in ex vivo human blood at 0 and 8 h after radiotracer incubation.
Furthermore, paraffin-embedded cross-sections of ex vivo human thrombi
(n= 3) were prepared for autoradiographic experiments performed in
quadruplicate; (i) 18F-ENC2015; (ii) 18F-ENC2015 co-incubated with
homologous unlabelled ‘cold’ ENC2015 (5lM); (iii) 18F-ENC2015
co-incubated with heterologous scrambled tracer (5lM); and (iv) 18F-
ENC2015 co-incubated with iodoacetamide (5lM), a non-selective irre-
versible inhibitor of all cysteine peptidases, which in this experimental
design works as negative control. All tissue sections were de-paraffinized,
rehydrated and incubated for 2 h at 37C, and then slides were washed
twice with phosphate buffer solution before being air-dried and exposed
to a Fujifilm BAS-IP MS 2040 phosphor screen (Fujifilm, Japan).
Porcine aortic strips from the Badimon chamber experiments were
imaged for macroscopic (Biospace Lab PhotonIMAGER Optima system,
France) and microscopic thrombus fluorescence (Zeiss Axio Scan.Z1,
Germany) on the Cy5 channel (645/670 nm wavelength excitation and
emission). Strips exposed to 18F-ENC2015 were imaged with the nano-
positron emission tomography-computed tomography (NanoPET/CT,
Mediso, Hungary) enabling quantification of tracer uptake. Phosphor
screens were imaged on a Fujifilm FLA5100 imaging plate reader (Fujifilm,
Japan).
Animal studies
All experiments were conducted in accordance with institutional animal
care protocols, authorized by the Home Office under the Animals
(Scientific Procedures) Act 1986 and conformed to EU guidelines
(Directive 2010/63/EU) of the European Parliament on the protection of
animals used for scientific purposes. Adult male rats (16.7 ± 3.8 weeks,
392.8 ± 74.1 g, n= 8) were anaesthetized with 2–2.5% isoflurane (50/50
oxygen/nitrous oxide, 1 L/min). Body temperature was maintained by
heated scanner bed or heated mat and monitored by a rectal thermom-
eter. Vital signs including heart rate and respiration rate were monitored
continuously during the experiments. Biodistribution was assessed in
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..three rats with 4 h of whole-body dynamic PET imaging after tail vein in-
jection of 18F-ENC2015 (17.6 ± 1.8 MBq, mean ± SD). Analysis of radio-
metabolites generated in vivo using HPLC was performed in a further two
rats after tail vein injection of 18F-ENC2015 (63.1 ± 19.2 MBq, mean ±
SD) with arterial blood sampled at 2, 30, and 60 min post-radiotracer in-
jection. About 1 mL of rat blood was manually collected at each time-
point to generate a population curve. Following blood collection, all
samples were kept on ice until analysed. Radioactivity in whole blood and
plasma was assessed using a well-type c-counter using a 400–1400 keV
window (Perkin Elmer Wizzard 2, USA). Plasma samples (400lL) were
processed by acetonitrile denaturation and analysed by HPLC (Ultimate
2000, Thermo Fisher, UK) on a Luna C18(2) column (Luna C18(2),
10 250 mm, 10lm, Phenomenex, UK) with a mobile phase of aceto-
nitrile and water at a flow rate of 4 mL/min to estimate the parent frac-
tion. A gradient elution from 95% water/5% acetonitrile to 5% water/95%
acetonitrile over 12 min was used. Mobile phases were prepared with
0.1% trifluoroacetic acid.
Thrombosis was induced in three rats following application of 10%
ferric chloride to the left common carotid artery.16 After a period of
10 min, 18F-ENC2015 (32.7 ± 2.7 MBq, mean ± SD, n= 3) was injected
as a bolus intravenous tail vein injection and animals underwent dy-
namic PET imaging up to 3 h post-injection. Animals were killed with
overdose of anaesthesia. From one animal, the thrombosed carotid
was harvested after sacrifice for autoradiographic analysis as for the
human thrombus.
Whole-body PET images were re-binned as follows: 7 1, 2 5, and
4 10 min per bed position. Dynamic PET images were re-binned as fol-
lows: 18 10 s, 2 30 s, 1 60 s, 2 2 min, 10 5 min, and 9 10 min.
A CT scan (semi-circular full trajectory, maximum field of view, 480 pro-
jections, 50 kVp, 300 ms, and 1:4 binning) was acquired at the end of each
emission scan to correct for attenuation and allow PET and CT image co-
registration. All PET images were reconstructed using Mediso’s iterative
Tera-Tomo 3D reconstruction algorithm and the following settings: four
iterations, six subsets, full detector model, low regularization, spike filter
on, voxel size 0.4 mm and 400–600 keV energy window. PET data were
corrected for random coincidences, scatter, and attenuation.
Image processing and analysis
After 24 h of fixation, macroscopic porcine strip fluorescence (Biospace
lab photon IMAGER) was determined by placing equal-sized regions of
interest over the thrombus in each experimental group and allowing 5 s
exposure in the Cy5 channel (Figure 2A). Following this, the proximal and
distal 1 mm of the exposed strip were discarded, and the remainder cut
into 8 segments. Each segment was subsequently snap-frozen with 5lm
sections prepared. Between 4 and 8 microscopic cross-sections were
then examined for thrombus fluorescence (Axioscan. Z1) in the Cy5
channel using equally sized regions of interest placed over the thrombus
(Figure 2C).
After micro-PET/CT imaging, PET and CT images of the aortic strips
were reconstructed, and radiotracer uptake was quantified on PMOD
3.405 software (PMOD Technologies, Switzerland). Equally sized vol-
umes of interest (VOIs) were drawn over the thrombus and uptake quan-
tified as kBq/mL (Figure 2B). To account for variation in infused
radioactivity between experiments tracer uptake was normalized by
dividing the total uptake within the VOI by the total infused activity in
MBq to give kBq/mL/MBq. Autoradiographic images of human and rodent
thrombus sections were exported into Fiji software17 where equally sized
region of interest’s were drawn on serial sections across each treatment
group and greyscale pixel intensity was calculated and compared be-
tween groups. Percentage specific binding (%SB) was calculated by sub-
tracting measured activity in tissue sections incubated with different
inhibitors (non-labelled ENC2015, scrambled peptide and iodoaceta-
mide) from sections exposed to 18F-ENC2015 only.
Animal PET images were fused with CT images to enable accurate co-
registration. In the animals undergoing biodistribution analysis, VOIs were
manually drawn around organs of interest and in the thrombus model
group, VOIs were drawn around the thrombosed carotid artery, contra-
lateral patent vessel and skin incision site (Figure 2D). Time-activity curves
were generated and standardized uptake values (SUVs) calculated as con-
centration in the VOI divided by injected dose divided by the animal
weight. Additionally, SUVs in each volume of interest were divided by the
corresponding left ventricular blood pool activity to give SUV ratios
(SUVr) and allow quantification of target:non-target ratios.
Figure 2 Demonstration of tracer uptake quantification in each experiment. (A and B) Regions of interest placed over the thrombus on the porcine
strip in both optical and PET studies are shown, respectively. (C) A cross-section Cy5-ENC2015-labelled thrombus with a ROI placed over the media
exposed to blood. The blue fluorescent stain is 40, 6-diamidino-2-phenylindole (DAPI), a commonly used nuclear counterstain to improve immuno-
fluorescence contrast. (D) An 18F-ENC2015 ROI placed over area of uptake within the rat left common carotid artery. ROI, region of interest
4 J.P.M. Andrews et al.
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For all studies, continuous variables are reported as mean ± standard
error of the mean, unless otherwise indicated in the text. Statistical ana-
lysis was performed by two-way analysis of variance with repeated meas-
ures and post hoc Dunnet’s or two-tailed Student’s paired t-test
(GraphPad Prism, version 7.0, Graph Pad Software, USA).
Results
ENC2015 binds to acute human
thrombus
Optical fluorescence
In both high and low shear thrombi, Cy5 labelled ENC2015 rapidly
bound to acutely formed thrombus (Figure 3A and G) with co-
infusion of iodoacetamide strongly inhibiting thrombus fluorescence
(Figure 3B and H). Control experiments of blood only (Figure 3C and
I) and ENC2015 without blood (Figure 3D and J) showed low levels of
fluorescence in comparison to Cy5-ENC2015 (Table 1). Reagent
controls (Figure 3E, F, K, and L) also showed low levels of fluorescence
in comparison with Cy5-ENC2015.
Positron emission tomography
Similar to the optical study, 18F-ENC2015 demonstrated avid uptake
to acutely formed human thrombus (Figure 4A and B) that was specific
for Factor XIIIa with uptake in both high and low shear thrombi
strongly inhibited by iodoacetamide (Table 2, Figure 4E and F). Uptake
of 18F-ENC2015 was greater in low shear than high shear thrombi
(0.96 vs. 0.5 kBq/mL/MBq, P= 0.02). After co-infusion of iodoaceta-
mide, 18F-ENC2015 thrombus binding was markedly reduced by
88% and 87% for low and high shear thrombi, respectively.
Autoradiographic sections of human thrombus (n= 3) showed
marked uptake of 18F-ENC2015 (Figure 4C) specifically blocked with
unlabelled ENC2015 standard (Figure 4D and Supplementary data on-
line, Figure S4Bii). Thrombus binding was reduced by 67% in low and
64% in high shear thrombi (Figure 4G) and 52% for rodent carotid
thrombus harvested from the in vivo model. Heterologous blocking
with a scrambled peptide showed a mean thrombus binding reduc-
tion of 20% in human thrombus and 18% in rodent carotid thrombus
(Supplementary data online, Figure 4Biii and S5Aiii). The alkylating
agent iodoacetamide had no effect on uptake in both human and ro-
dent explanted thrombus (Supplementary data online, Figure 4iv).
18F-ENC2015 is rapidly cleared from non-target tissues
and has slow metabolism in vivo
Using HPLC, in vivo detection of radiometabolites in rat blood found
100% of the parent compound present at 2 min after intravenous
bolus administration, 69.7± 9.8% after 30 min and 42.0 ± 0.5% after
60 min, with only one other peak indicating a single major polar
Figure 3 Binding of Cy5-ENC2015 to acutely formed human thrombus. (A–F) Histological cross-sections of the porcine aortic strips at20 magni-
fication (sectioned at yellow dotted line in panel G). (G–L) Macroscopic fluorescence of the corresponding sections above is demonstrated. Note
clear thrombus fluorescence in A and G with corresponding brightfield direct antibody stain to factor XIIIa (A inset). (M–P) Sequence 1 in bar charts
demonstrates the tracer binding to both low and high shear thrombi and how this is specifically blocked by the administration of a factor XIII inhibitor
(Sequence 2) and how it can clearly be distinguished from the autofluorescence of blood (Sequence 3). Values expressed as mean ± SEM, n= 6
(paired two-way ANOVA). Asterisk shows thrombus enhancement on histological cross-sections.
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radiometabolite (Figure 5A–D). In all animals, 18F-ENC2015 was rapid-
ly cleared from the vascular bed, heart, and lungs and was predomin-
antly excreted via the kidneys (Supplementary data online, Figure S5).
The mean percentage of total injected 18F-ENC2015 in each major
organ over time can be seen in Table 2. Radiometabolite analysis of ex
vivo human blood using HPLC found the parent 18F-ENC2015 com-
pound to remain unmetabolized after 8 h post-incubation
(Supplementary data online, Figure S3).
18F-ENC2015 binds to thrombus in vivo
Rapid and high uptake of 18F-ENC2015 was observed in the carotid
thrombus and skin incision site in all animals (Figure 6B and C). Mean
thrombus SUVr began to surpass contralateral vessel SUVr 10 min
after injection. Thrombus SUVr peaked at 130 min with separation of
the activity curves maintained after 180 min post-radiotracer adminis-
tration (Figure 6C). Mean activity in the thrombosed vessel was higher
than in contralateral vessel from 35 to 180 min (P< 0.0001, paired
t-test).
Discussion
Here, we presented the synthesis and pre-clinical evaluation of
ENC2015, a dual-purpose optical and PET Factor XIIIa targeted
probe for detecting thrombi. In a translational model of deep vascular
injury, we successfully demonstrated rapid and SB of ENC2015 to
....................................................................................................................................................................................................................
Table 1 Optical tracer uptake in ex vivo translational model of human thrombus formation
Sequence ENC20151blood
(Sequence 1)
ENC20151blood
1 inhibitor (Sequence 2)
Blood only
(Sequence 3)
P value
(1 vs. 2)
P value
(1 vs. 3)
fluorescence
Low shear macroscopic (ph/s/cm2/sr) 4.4 107 ± 0.89 107 0.33 107 ± 0.13 107 1.16 107 ± 0.67 107 0.01 0.01
Low shear microscopic (AU) 7307 ± 403 3297 ± 30 3103 ± 48 <0.0001 <0.0001
High shear macroscopic (ph/s/cm2/sr) 6.38 106 ± 2.3 106 1.22 106 ± 0.45 106 1.24 106 ± 0.67 106 0.09 0.05
High shear microscopic (AU) 4966 ± 118 3356 ± 53 3078 ± 29 <0.0001 <0.0001
Each row represents thrombus type and quantification method used to analyses tracer uptake with each column representing the constituents of each experimental run. Tracer
uptake in Sequence 1 (blood þ tracer) was significantly greater than 2 (blood þ tracer þ inhibitor) and 3 (blood only) in all thrombi bar the macroscopically analysed high shear
thrombi. Data are shown as mean ± SEM (n= 6; paired two-way ANOVA).
Figure 4 Binding of 18F-ENC2015 to acutely formed human thrombus. (A) Avid thrombus binding of 18F-ENC2015 on Micro-PET CT similar to
optical version of ENC2015. (B) Diminished thrombus uptake of the radiotracer in the presence of factor XIIIa inhibitor. (C) An autoradiographic
plate showing uptake of 18F-ENC2015 on sections (5lm thickness) of freshly formed human thrombus. (D) Corresponding serial sections pre-
treated with cold tracer demonstrating specific inhibition of binding sites. Bar charts (Eþ F) demonstrate 18F-ENC2015 tracer uptake in both low
and high shear thrombi (Sequence 1) and how this is specifically blocked by a factor XIII inhibitor (Sequence 2) (n= 10). (G) Bar chart shows a marked
and significant reduction in 18F-ENC2015 uptake in human thrombus co-incubated to unlabelled tracer (n= 3). Values expressed as mean ± SEM,
(paired t-test).
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..human thrombus. Fluorescence and 18F-ENC2015 uptake in low
shear thrombi were markedly greater than in high shear thrombi
which reflect greater fibrin deposition and factor XIIIa activity in
acutely formed thrombi formed in a slow flowing venous system.18,19
However, uptake of both probes was easily appreciable in the high
shear, classically platelet-rich ‘white thrombus’20 illustrating the versa-
tility of ENC2015 to identify both venous and arterial thrombi.
To further enhance understanding of the relationship between fibrin
deposition and platelet binding in both high and low shear thrombi, a
comparison of ENC2015 with a platelet binding probe such as that
reported by Kim et al.7 would be insightful.
Previous work on NC100668 deduced the major site of me-
tabolism to be the renal cortex with a small fraction metabo-
lized by proteases in the blood.8,11,21 Given the chemical
similarity between the two peptides, it is likely that ENC2015
would undergo similar metabolic pathways as NC100668. Our
analysis found the production of one major in vivo metabolite
(Metabolite A, Figure 5, Graph CþD). This compound was only
identified from in vivo rat blood sampling and was not found
after 8 h of 18F-ENC2015 incubation in ex vivo human blood.
This demonstrates that uptake within human thrombus formed
in the Badimon chamber studies must therefore be due to the
activity of the parent compound and not a human blood-
formed metabolite. Furthermore, it highlights the stability of
Figure 5 In vivo metabolism of 18F-ENC2015 in rat blood. (A) Graph shows the radioactive concentration of 18F-ENC2015 over time in rat
whole blood and plasma (n= 2). (B) HPLC analysis in chromatogram shows a single peak of parent compound after 2 min of in vivo 18F-ENC2015 cir-
culation. (C) After 30 min, a second smaller peak ‘metabolite A’ can be appreciated on chromatogram. (D) At 60 min, chromatogram shows the radio-
activity of metabolite A surpassing that of the parent compound.
.................................................................................................
Table 2 Organ biodistribution of 18F-ENC2015 over
time
% ID 1 h 4 h
Heart 0.071 ± 0.016% 0.009 ± 0.001%
Lungs 0.061 ± 0.006% 0.014 ± 0.003%
Kidneys 16.542 ± 1.113% 14.938 ± 0.645%
Bladder 33.498 ± 4.769% 17.14 ± 3.564%
Liver 0.107 ± 0.025% 0.031 ± 0.015%
Brain 0.011 ± 0.001% 0.001 ± 0.0002%
Note the rapid reduction in decay corrected percentage of injected radioactivity
from 1 h to 4 h in all analysed organs. Tracer accumulation was greatest in the kid-
neys owing to a renal site of metabolism and excretion. Data are shown as mean
± SEM (n= 3).
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..18F-ENC2015 in human blood and (in conjunction with in vivo
biodistribution data showing renal cortex concentration) is con-
sistent with a renal site of metabolism previously reported in
both rats and humans.11 Importantly, (and consistent with our
in vivo findings), plasma clot uptake assays from Edwards et al.10
using 99mTc-NC100668 reported this single major metabolite to
have little impact on clot imaging ability.
Forty percent of total injected 18F-ENC2015 remained stable
in vivo after 1 h incubation which compares with 60% of another
promising potentially translatable fibrin probe studied in rats, 111In-
FBP15, but is lower than 64Cu-FBP8 (>95%).22 Unlike these probes,
ENC2015 is labelled with fluorine-18, which has a half-life of 110 min
(compared with 12.7 h for copper-64 and 2.8 days for Indium-111)
thereby reducing effective residency times in organs for equal dose
regimens and enhancing image quality owing to the more favourable
physical decay characteristics of fluoride-18 vs. copper-64 or indium-
111. When compared with SPECT, fluoride-18 PET imaging also pro-
vides better sensitivity through improved image resolution, shorter
scan time and more straightforward quantification.23,24 Furthermore,
when compared with conventional 18F-labelling, the aluminium fluor-
ide method provides greater yields more rapidly and is flexible for vir-
tually any peptide NOTA structure.25
In the well-validated ferric chloride model of rodent arterial
thrombosis,16,26 in vivo efficacy of 18F-ENC2015 thrombus binding
was demonstrated with favourable thrombus to blood pool ratios.
Tracer uptake within the thrombosed vessel was greater than the
contralateral vessel from 10 min to 2 h after injection, confirming 18F-
ENC2015 as a highly sensitive early marker of fibrin crosslinking.6,27
Importantly thrombus to blood pool SUVr were maintained between
2:1 and 3:1 after 3 h of dynamic imaging, indicating ongoing FXIIIa de-
pendent fibrin crosslinking and easily appreciable discrimination of
thrombus from healthy tissue at 3 h. Finally, autoradiographic studies
of human and rodent thrombus showed clear selectivity of 18F-
ENC2015 to target both human and rodent thrombus albeit with
some degree of non-SB (which is not uncommon for small peptides
exposed to fixed tissue).28 Factor XIIIa is responsible for formation of
covalent crosslinks between residues of target proteins, stabilizing
the fibrin clot structures through crosslinking of fibrin polymers to in-
crease stiffness, reduce stretch, and limit plasmin-mediated proteoly-
sis. Previous studies have shown factor XIIIa is expressed in joints and
the levels of this coagulation transglutaminase changes during osteo-
articular diseases. In agreement with those previous observations,
the PET signal measured in the joints with 18F-ENC2015 (Figure 2D)
is consequent of target expression at those sites.29
18F-ENC2015 thrombus to background SUVr were similar to rat
intra cardiac thrombus binding of fibrin probe 64Cu-FBP8 (reported
by Blasi et al.22,30) but less than 111In-FBP15 as assessed by SPECT
(which reached thrombus to contralateral SUVr of greater than 4:1).
Whilst, we explored the role of 18F-ENC2015 in occlusive carotid ar-
terial thrombi, tracer localization to the surgical skin incision demon-
strated similar (but not identical) binding profile. This is important for
two reasons; more rapid uptake within the skin incision and an earlier
plateau than the arterial thrombosis (Figure 6B and C) supports our
Badimon chamber findings of greater uptake within acutely formed
low shear, fibrin rich thrombi. However, uptake within the arterial
thrombus surpasses the skin incision with time illustrating the dichot-
omous process of fibrin cross-linking in the two vascular spaces.
Conversely, the similarity of the binding profiles between skin incision
and arterial thrombus renders non-specific tracer pooling from a res-
ervoir or ‘leaky vessel’ effect unlikely. This unique binding pattern
reinforces the versatility of our chosen peptide. This is clinically rele-
vant as constituent differences form the rationale behind differing
drug targets for arterial and venous thromboses. Thrombi rich in ac-
tively cross-linking fibrin are more prone to therapeutic lysis with tis-
sue plasminogen activators than those that have completed
crosslinking.31 Correspondingly, thrombi propagated by rapid
Figure 6 Biodistribution and thrombus binding of 18F-ENC2015 in rats. (A) Images of the time-averaged uptake within the thrombus and skin inci-
sion compared with the contralateral vessel. (B) A decay corrected time activity curve showing 18F-ENC2015 kinetics (mean SUV, n= 3) within our
in vivo thrombosis model. Note the rapid blood pool clearance of 18F-ENC2015 with early uptake in the skin incision which tails off to equilibrate simi-
larly to the arterial thrombus between 60 and 90 min (pseudo-equilibrium). (C) The mean change in SUV ratio of the thrombosed vessel compared
with contralateral vessel and LV blood pool over time (n= 3) was demonstrated. Thrombus vs. contralateral vessel SUV from 35 to 180 min P-value
< 0.0001 (paired t-test).
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..platelet activation are more likely to respond to anti-platelet therapy,
therefore, identification of both processes may be useful to inform
decision making to determine optimal time points for drug therapy.
Whilst single modality PET imaging appears to hold promise in the
field of cardiovascular thrombus imaging, the combination of dual
labelled probes incorporating advantages of both optical and PET
tracers is also now possible.32–34 Once bound to their target the
decay of a fluorophore depends on exposure time to a specific wave-
length of light. Typically, this is very slow meaning tissue can be histo-
logically characterized sometime afterwards if required. Ultimately
dual-labelled agents could be used for diagnosis, treatment and pro-
cedural planning, therapeutic monitoring, and validation of histologic-
al findings; an exciting prospect for the future.
Conclusion
Overall our pre-clinical evaluation has shown that 18F-ENC2015 is a
selective fibrin directed radiotracer which is rapidly cleared from
background tissues, excreted predominantly via the urinary system
with potential for highly sensitive and specific imaging of both venous
and arterial thrombi. Investigation of radiolabelled FXIIIa probes like
18F-ENC2015 has the potential to improve our understanding of
real-time thrombus formation in both arterial and venous systems.
Furthermore, the use of thrombus radiotracers may increase diag-
nostic accuracy and allow optimization of anti-thrombotic and anti-
coagulant therapies across a broad spectrum of thrombotic
disorders.
Supplementary data
Supplementary data are available at European Heart Journal - Cardiovascular
Imaging online.
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